3/16/2022

speaker
Operator
Conference Call Operator

And welcome to CTIA's fourth quarter and full year 2021 earnings call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded and at CTIA's request. I would now like to turn the call over to Lisa Hayes, Vice President of Investor Relations and Corporate Communications.

speaker
Lisa Hayes
Vice President of Investor Relations and Corporate Communications

Good afternoon and welcome to CITIER's conference call that will focus on fourth quarter and full year 2021 financial and operational results and discuss our objectives for 2022. With me on the call today with prepared remarks are Dr. Marcus Rentschler, our President and Chief Executive Officer, and Dave Gallero, our Vice President of Finance. Andrew Jenjoff, our Chief Business Officer, and Paul Seacrest, our Chief Scientific Officer, will join for Q&A. I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. With that, I will turn the call over to Marcus.

speaker
Dr. Marcus Rentschler
President and Chief Executive Officer

Thanks, Lisa. 2021 was an exciting year for Psych-Tier with solid execution and advancement of our lead program, CYT0851, as we met key clinical objectives discussed during our IPO in June. Importantly, we entered the next stages of clinical development, Phase II monotherapy and Phase I in combination with chemotherapy. We have strengthened our management, clinical, and research teams, which positions us well to achieve multiple key milestones in 2022, including reporting data from the monotherapy and combination studies with CYT0851. But before I preview 2022 in more detail, let me summarize the accomplishments we've made over the past year. As a reminder, our lead product candidate is CYT0851. which is designed to inhibit DNA repair. This novel and patented drug is in a Phase I study in combination and a Phase II study as monotherapy in patients with relapsed or refractory hematologic malignancies and solid tumors. As is typical of such studies, we are evaluating the safety of CYTO851 in patients who have failed multiple cancer therapies and who have exhausted all available therapeutic options while exploring early signs of efficacy. These patients have progressive tumors and need an effective treatment. If CYTO851 is shown to be safe and efficacious in these heavily pretreated patients with poor prognosis, we'll look for opportunities to bring CYTO851 into earlier lines of therapy. Over the past year for CYTO851, we completed the Phase I portion of our trial and determined the recommended Phase II dose. In this dose escalation portion of the first in-human trial of CYTO851, we escalated the dose 40-fold in 12 cohorts and determined the maximum tolerated dose of 600 milligrams per day and a recommended Phase II dose of 400 milligrams per day taken orally once a day. We're pleased with this dose recommendation. This dose level, if proven effective, should be straightforward for patients to manage as a once-daily medication schedule is convenient and easy to follow. An interim analysis of our ongoing Phase I-II study of CYTO851, as presented previously, showed that CYTO851 provided disease control in 20 of 46 response-evaluable patients, including three responses in non-Hodgkin lymphoma and soft tissue sarcoma. On a standalone basis, this data is encouraging. It is further encouraging considering the high unmet need in patients so heavily pretreated prior to their participation in our study. Furthermore, the safety profile shown in these patients is quite encouraging. CYTO 851 has been well tolerated today, which differentiates it from other phase one drugs given the level of activity we are observing. Of the 73 patients enrolled in the study, 58% reported at least one treatment-related adverse event, and only 16% of patients reported at least one grade 34 treatment-related adverse event. Importantly, across all dose levels, 42% of patients had no treatment-related adverse events. Most importantly, we have not observed any clinically significant myelosuppression, neuropathy, vomiting, or diarrhea, which are some of the most common adverse events that post challenges in drug development. The adverse events reported at the recommended Phase II dose are primarily low-grade. The three most common treatment-related adverse events were fatigue reported by 21% of patients, hyperuricemia reported by 11% of patients, and nausea reported by 11% of patients. No patient at or below the recommended Phase II dose discontinued treatment for treatment-related adverse events. In 2021, we demonstrated CYTO851 clinical proof of concept with disease control and radiologic responses with a safety profile consisting primarily of mild grade 1 and 2 treatment-related adverse events. Now, while we're encouraged by these data, we recognize that the study of CYTO851 remains early. We're eager to see further clinical results from our CYTO851 studies. The Phase 1-2 study of CYT0851 as a monotherapy continues. Before the end of 2022, we anticipate reporting additional data from this study. At the start of 2022, we were ready to initiate six Phase 2 monotherapy expansion cohorts in solid tumors and hematologic malignancies as part of our ongoing Phase 1-2 trial. The first patient was enrolled in January 2022. Before the end of this year, we anticipate data from these expansion cohorts. Preclinical, in vitro, and in vivo data demonstrate synergy or additivity when certain chemotherapy drugs were combined with CYT0851. Once we established that CYT0851 did not cause significant myelosuppression in humans, it allowed us to begin the evaluation of CYT0851 in combination with standard-of-care anticancer therapies with the first patient enrolled in December. Similar to our monotherapy expansion cohorts discussed earlier, we anticipate reporting data before the end of 2022. I will further describe these combination studies in a moment. It is not only CYTO 851 which has us encouraged. From our discovery platform, in 2021, we advanced two additional targets in distinct DNA damage response pathways to nomination and I've moved those into high-throughput screening to identify lead compounds. The first of these undisclosed new targets, Target 2, plays a key role in non-homologous N-joining, or NHEJ, and the second, Target 3, in microhomology-mediated N-joining. Both of them are DNA repair pathways. For both targeted drug discovery projects, we have identified subsets of cancer patients that we believe uniquely depend on the target of interest for their survival, and we're working to identify patient selection biomarkers to identify these cancer subsets for use in drug candidate development. Both undisclosed target projects are currently in lead generation and will enter the lead optimization stage in 2022. For these targets, rather than use a phenotypic screen as we did for CYT0851 and 1853, we are using a more traditional drug discovery approach by first identifying the molecular target of interest, then developing assays to measure the inhibition of its function, and screening for molecules that inhibit the protein from carrying out DNA repair functions. Both undisclosed target projects are in preclinical stage, and we anticipate reaching the drug candidate nomination stage in 2023. CYT1853 was developed as a next-generation drug to be more potent than CYT0851, thus potentially could be used to treat cancers not treated well with CYT0851 or that have become resistant to it. In 2021, we advanced CYT1853 towards an IND, and by the end of 22, we should be able to define the development path for this product candidate. We are completing IND-enabling toxicology studies with 1853 in the first half of 22, and if the data supports an overall risk-benefit improvement and differentiation from CYTO 851, we plan to file an IND by year-end 22. In addition to our progress in advancing our multiple product candidates, other notable highlights for 2021 include we further strengthened our teams. We expanded our chemistry, discovery biology, and translational teams and laboratory footprint to support our goal to become a leading biotech company developing and commercializing next-generation precision oncology medicines that inhibit DNA damage response and cause cancer cell death through synthetic lethality. We've been able to recruit highly accomplished and talented people dedicated to bringing new cancer therapies to patients who need them so desperately. I'm proud that the team works effectively together, and despite the challenges of the pandemic and a robust job market, that we have experienced minimal employee turnover. We've built a high-energy, high-performance team that is incredibly collaborative and productive and is motivated to work on promising opportunities, as is the core of Cypher's operations. As Dave will discuss in a moment, we have a strong cash position, and based on our current plans, we believe that our current capital resources are efficient to fund operations into 2024. I want to thank our current investors for your support and to express thanks to all investors who participated in our IPO in 2021. Our strategy has not changed, and we continue to execute on the objectives we set forth in the IPO to bring CYTO 851 to patients with a high-end need and to expand our portfolio. We think that there's considerable value in our pipeline and platform and are hopeful that investors will take notice of our progress and upcoming milestones. Before Dave provides details on our financial results, I would add some further comments about our lead product candidate, CYTO 851. Through these comments, I hope you gain additional insight into our progress and outlook. The CYTO851 data I commented on earlier was based on data from a November 15, 2021 cutoff of our Phase I dose escalation study. As previously reported, CYTO851 was used to treat a total of 73 patients, of whom 46 patients, or 63%, were considered responsive-valuable per protocol. 20 patients of 43% had a best response of stable disease or better. One patient experienced a complete response that is still ongoing. Two patients experienced a partial response. And 17 patients experienced stable disease. 26 patients experienced progressive disease. As a reminder, all of these patients entered the trial having failed multiple lines of prior therapy and had exhausted standard therapies. The disease was progressing prior to the study treatment such that getting a clinical response is expected to be unlikely. Witnessing favorable disease stabilization from 43% of these high-risk patients is quite encouraging. In solid tumors, there was a partial response in one sarcoma patient that was not confirmed primarily for technical reasons. Notably and encouragingly, the patients stayed on treatment for about a year, and from an initial 25 centimeter total target tumor burden experienced reduction by over 30% while on study. We had 16 patients with stable disease across several solid tumors. About half of those have tumor shrinkage, including pancreatic cancer, head and neck cancer, ovarian cancer, and other sarcomas. In hematologic malignancies, we saw one confirmed complete response in the follicular lymphoma patient who entered the trial with bulky, greater than 10 centimeter disease after five prior lines of therapy. The patient continues to be in complete remission and is continuing therapy to date. We also observed a confirmed partial response in a diffuse large B-cell lymphoma patient who had more than 100 metastases that, within two months, became PET negative. As of the November data cut, we also had one patient with stable disease. This is remarkable given how advanced this patient's disease was. Duration of treatment is an important indicator of disease control in oncology and of drug safety. There were 16 patients that had been treated for four months or longer, suggesting that there's clinical benefit with CYT0851 treatment. When we looked at the treatment duration of their last prior therapy as a control, we found that 13 out of those 16 patients received CYT0851 longer than their last prior therapy, which was often an active chemotherapy drug. Of the 73 patients, 19 or 26% were still on treatment as of the November 15th, 21 data cutoff. We plan to present the full data set from the phase one dose escalation study at a medical congress in June if accepted for presentation. As discussed, we've expanded our clinical study of CYTO851, building upon the differentiated safety profile and encouraging preliminary single agent activity of the drug. We're currently dosing patients in six cohorts in the phase two monotherapy expansion study in pancreatic cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma, follicular lymphoma, and multiple myeloma. We are also enrolling in three phase one combination cohorts with three approved standard of care anti-cancer therapies, capecitabine, the oral form of 5-fluorouracil, and gemcitabine for solid tumors, and rituximab plus bendamustine for NHL. We expect to have preliminary safety data for the Phase I combination cohorts and to have completed the first stage of the Phase II monotherapy cohorts before the end of 2022. We're also working on identifying a patient selection biomarker and elucidating the mechanism of action of CYTO-851. Recall that 851 was identified through a phenotypic screening strategy that exploited a novel synthetic lethality between cytidine deaminase overexpression and homologous recombination inhibition. The screen was designed to select for compounds that induced synthetic lethality in cytidine deaminase overexpressing cancer cells while sparing normal cells. By its nature, this type of screening strategy does not depend on nor directly lead to a precise understanding of where the active drug candidates bind nor the precise mechanism of action. A better understanding of the binding site of CYT0851 will allow us to hone in on the patients most likely to respond. While CYT0851 advances in clinical testing, we continue to make progress on elucidating its molecular target and mechanism of action and plan on updating you during the year on our progress. The diseases we're exploring in our Phase I-II trial, pancreatic cancer, sarcoma, ovarian cancer, multiple myeloma, diffuse large B-cell lymphoma, and follicular lymphoma, have large populations who have no additional therapy available to them, either because they've exhausted them or because they're too frail to receive them. An oral agent that's well-tolerated and either has sufficient monotherapy activity or can be combined with active standard therapies, may be able to provide meaningful clinical benefit for these patients. Coming out of 2022, we anticipate having the design for a Phase II trial with registrational intent to pursue one or more indications for CYTO851. As we begin 2022, The Cytir team continues to execute on enrolling our clinical trial, advancing our preclinical target programs, further elucidating the CYTO851 mechanism of action, and identifying a potential biomarker to improve patient selection. We expect to have safety data on the Phase I CYTO851 combination cohorts and data from the completion of the first stage of the Phase II monotherapy cohorts. We have already made considerable progress in 2022 and look forward to updating you on our progress throughout the year. With that, I'd like to turn the call over to Dave Gallero to review the fourth quarter financials. Dave?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-